Although the clinical indications of most A2AR drugs are cardiovascular and neurological diseases, increasing preclinical studies and clinical trials have already confirmed the feasibility of A2AR blockade as a new therapeutic strategy for cancer. The gene discussed is ADORA2A; the disease is cancer.